Ensuring Successful M&A And Leading In An Increasingly Regulated Business World.
During her time at GSK, Sarah oversaw one of the biggest UK corporate de-mergers of the 21st century. The end product listing, Haleon, was a whopping £28.5bn. She also led the transatlantic joint venture between GSK and Pfizer worth £9.8bn. Sarah shares incredible insight into making a merger and de-merger work as well as a look into what it’s like to lead in a business world of increasing risk surrounding cyber and digital as well as increasing ESG-related regulations.